A diagnosis of hepatocellular carcinoma (HCC), the most common type of liver cancer, was once associated with very limited treatment options. For years, patients and physicians had only a few therapies available, and outcomes remained difficult for many people living with the disease.
Today, the landscape looks very different.
Advances in immunotherapy, targeted treatments, and combination therapies have expanded treatment choices and improved survival prospects for many patients. Several pharmaceutical companies have played a major role in driving this progress through years of research, clinical trials, and investment in liver cancer drug development.
The need for better treatments remains substantial. Liver cancer is the sixth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related death. In 2022, approximately 866,000 new liver cancer cases and nearly 759,000 deaths were reported globally. Hepatocellular carcinoma accounts for around 75% to 80% of all liver cancer cases, making it the most common form of the disease.
Roche: Setting a New Treatment Standard
Roche has been one of the most influential companies in modern hepatocellular carcinoma research.
The company’s combination therapy, Tecentriq and Avastin, marked a major shift in how advanced HCC is treated. The treatment demonstrated that combining immunotherapy with anti-angiogenic therapy could improve outcomes compared with previous standards of care.
Its success established a new first-line treatment option for many patients with advanced liver cancer and encouraged broader research into combination-based approaches across the industry.
AstraZeneca: Building New Immunotherapy Options
AstraZeneca has strengthened its position in liver cancer research through its focus on immunotherapy.
The company’s combination of Imfinzi and Imjudo introduced another important treatment option for patients with unresectable hepatocellular carcinoma. By targeting different immune pathways, the therapy was designed to help the body’s immune system recognize and attack cancer cells more effectively.
Positive clinical trial results helped expand treatment choices and further increased interest in immunotherapy-based strategies for HCC.
Bristol Myers Squibb: Advancing Long-Term Survival
Bristol Myers Squibb has become a key contributor to liver cancer treatment through its immuno-oncology portfolio.
Its therapies Opdivo and Yervoy have been studied extensively in advanced HCC. Clinical trial findings showed encouraging long-term survival outcomes for patients receiving the dual immunotherapy combination.
Data demonstrated that approximately 38% of patients treated with Opdivo and Yervoy were alive after three years, compared with 24% of patients receiving standard treatments such as sorafenib or lenvatinib. These results highlighted the growing role of immunotherapy in extending survival.
Merck & Co. and Eisai: A Long-Term Commitment to HCC Research
Merck & Co. and Eisai have maintained a strong presence in hepatocellular carcinoma research through ongoing clinical development programs.
Eisai’s Lenvima became one of the most widely used targeted therapies for advanced HCC and remains an important treatment option worldwide. The drug is frequently used as a benchmark in clinical studies evaluating newer therapies.
Merck’s Keytruda has also been evaluated across multiple liver cancer trials. While some late-stage studies produced mixed results, both companies continue to invest in research aimed at improving outcomes for patients with advanced liver cancer.
Bayer: The Early Pioneer
Before the rise of immunotherapy, Bayer helped establish the foundation for systemic treatment in hepatocellular carcinoma.
Its drug Nexavar became the first therapy to demonstrate a meaningful survival benefit in patients with advanced HCC following its approval in 2007. For many years, it remained the standard treatment option for advanced liver cancer.
The success of Nexavar helped attract greater investment into liver cancer research and opened the door for the next generation of targeted and immunotherapy treatments.
Leading Pharmaceutical Companies in HCC Research
| Company | Key HCC Therapy | Primary Research Focus |
|---|---|---|
| Roche | Tecentriq + Avastin | Immunotherapy combinations |
| AstraZeneca | Imfinzi + Imjudo | Dual immunotherapy |
| Bristol Myers Squibb | Opdivo + Yervoy | Checkpoint inhibitors |
| Merck & Co. | Keytruda | Immunotherapy development |
| Eisai | Lenvima | Targeted therapies |
| Bayer | Nexavar | Kinase inhibitor therapies |
Major Therapies Shaping the HCC Market
| Therapy | Company | Treatment Category |
| Tecentriq + Avastin | Roche | Immunotherapy + Anti-VEGF |
| Imfinzi + Imjudo | AstraZeneca | Dual Immunotherapy |
| Opdivo + Yervoy | Bristol Myers Squibb | Checkpoint Inhibitors |
| Keytruda | Merck & Co. | PD-1 Inhibitor |
| Lenvima | Eisai | Tyrosine Kinase Inhibitor |
| Nexavar | Bayer | Tyrosine Kinase Inhibitor |
Research in hepatocellular carcinoma continues to move forward as companies explore new treatment approaches. Scientists are investigating personalized therapies, biomarker-guided treatments, cell therapies, and next-generation immunotherapies to address unmet patient needs.
The challenge remains significant. Global liver cancer incidence is expected to increase over the coming decades, driven by factors such as chronic hepatitis infections, alcohol-related liver disease, obesity, and metabolic disorders.
As pharmaceutical companies continue investing in clinical development, the future of hepatocellular carcinoma treatment is expected to bring more therapeutic options and improved outcomes for patients worldwide.
Get Easy Access
Everything you need to understand the Pharmaceutical Market is now at your fingertips. Our experts provide a platform that combines statistical data, country insights, competitor analysis, and strategic trends in one simple, interactive space. No more wasting hours on scattered reports — just clear, actionable insights to guide your business forward. Visit and access the dashboard to stay ahead of the market curve effortlessly.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting firm whcih provides strategic intelligence and research expertise across the pharmaceutical market, including branded drugs, generic medicines, biologics, biosimilars, specialty pharmaceuticals, OTC products, and drug delivery systems. We support pharmaceutical companies with market analysis, pipeline assessment, and competitive insights to help drive innovation, strengthen commercialization strategies, and capture emerging growth opportunities in the evolving healthcare landscape.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium